Electricity tracing method of generation and loss cost allocation

2000 ◽  
Author(s):  
Y.Z. Li
Keyword(s):  
Cost Allocation ◽  
Tracing Method

scholarly journals Transmission Usage and Cost Allocation Using Shapley Value and Tracing Method: A Comparison

2014 ◽  
Vol 3 (3) ◽  
pp. 11-29 ◽  
Author(s):  
Pawan Rathore ◽  
Ganga Agnihotri ◽  
Baseem Khan ◽  
Garima Naidu
Keyword(s):  
Shapley Value ◽  
Cost Allocation ◽  
Tracing Method

scholarly journals Generator reactive power pricing for practical utility system using power flow tracing method

2018 ◽  
Vol 7 (1.8) ◽  
pp. 20
Author(s):  
Danalakshmi D ◽  
Kannan S ◽  
Gnanadass R
Keyword(s):  
Power System ◽  
Power Flow ◽  
Cost Allocation ◽  
Reactive Power ◽  
Restructured Power System ◽  
Optimal Reactive Power Dispatch ◽  
Power Dispatch ◽  
Power Flow Tracing ◽  
Reactive Power Dispatch ◽  
Tracing Method

The shift from regulated to restructured power system results in an increased competition among the electricity market. In restructured power system, the separation of transmission services from generation and distribution makes it necessary to find the contribution of power from individual generator to individual load. The power flow tracing method is used to obtain the generator power output to a particular load. The reactive power has to be maintained in order to sustain the voltage level throughout the system for reliable and secure operation. Hence the reactive power cost allocation has become imperative in the power system. In this paper, the tracing method is integrated with the optimal reactive power dispatch problem to trace the generator minimal reactive power for sustaining the real power transaction and enhancing the system security by meeting the demand. The Differential Evolution is used for optimal reactive power dispatch. The cost allocation to the generators for the reactive power service based on the opportunity cost method is obtained for 62 Bus Indian Utility Systems.

An online cost allocation model for horizontal supply chains

2021 ◽  
Vol 122 ◽  
pp. 102888
Author(s):  
Han Zou ◽  
Maged M. Dessouky ◽  
Shichun Hu
Keyword(s):  
Supply Chains ◽  
Cost Allocation ◽  
Allocation Model

A Cost-effectiveness Analysis of Aspirin versus Oral Anticoagulants after Acute Myocardial Infarction in Italy

1998 ◽  
Vol 80 (12) ◽  
pp. 887-893 ◽  
Author(s):  
Jacopo Gianetti ◽  
Gianfranco Gensini ◽  
Raffaele De Caterina
Keyword(s):  
Myocardial Infarction ◽  
Coronary Artery Disease ◽  
Cost Effectiveness ◽  
Interventional Procedures ◽  
Cost Allocation ◽  
Oral Anticoagulants ◽  
The United States ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis ◽  
Artery Disease

SummaryAims. The recent publication of two large trials of secondary prevention of coronary artery disease with oral anticoagulants (WARIS and ASPECT) has caused a revival of the interest for this antithrombotic therapy in a clinical setting where the use of aspirin is common medical practice. Despite this, the preferential use of aspirin has been supported by an American cost-effectiveness analysis (JAMA 1995; 273: 965). Methods and Results. Using the same parameters used in that analysis and incidence of events from the Antiplatelet Trialists Collaboration and the ASPECT study, we re-evaluated the economic odds in favor of aspirin or oral anticoagulants in the Italian Health System, which differs significantly in cost allocation from the United States system and is, conversely, similar to other European settings. Recalculated costs associated with each therapy were 2,150 ECU/ patient/year for oral anticoagulants and 2,187 ECU/patient/year for aspirin. In our analysis, the higher costs of oral anticoagulants versus aspirin due to a moderate excess of bleeding (about 10 ECU/ patient/year) and the monitoring of therapy (168 ECU/ patient/year) are more than offset by an alleged savings for recurrent ischemic syndromes and interventional procedures (249 ECU/ patient/year). Conclusions. Preference of aspirin vs. oral anticoagulants in a pharmaco-economical perspective is highly dependent on the geographical situation whereupon calculations are based. On a pure cost-effectiveness basis, and in the absence of data of direct comparisons between aspirin alone versus I.N.R.-adjusted oral anticoagulants, the latter are not more expensive than aspirin in Italy and, by cost comparisons, in other European countries in the setting of post-myocardial infarction.

Sign in / Sign up

Export Citation Format

Share Document